News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amarin Corporation PLC (AMRN) Release: AMR101 Phase 3 Study Data in Patients With Diabetes Mellitus (Type 2) to be Presented at the American Diabetes Association's 72nd Scientific Sessions


6/4/2012 10:05:43 AM

BEDMINSTER, N.J., and DUBLIN, Ireland, June 4, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, today announced that data from the AMR101 pivotal Phase 3 ANCHOR study will be presented in a poster at the American Diabetes Association's (ADA) 72nd Scientific Sessions at the Pennsylvania Convention Center in Philadelphia, Pennsylvania on June 9, 2012.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES